Rethinking Menopause Hormone Therapy - Takeaways - MDSpire

Rethinking Menopause Hormone Therapy

A JAMA Perspective outlines how updated FDA labeling may reshape menopause care.

  • By

  • Kerri Miller

  • April 23, 2026

  • 3 min

Share

  • 1

    Menopausal hormone therapy (MHT) use declined from over 20% to under 5% after the Women’s Health Initiative.

  • 2

    The FDA's removal of black box warnings on MHT presents an opportunity for improved patient care.

  • 3

    Research shows that initiating MHT before age 60 or within 10 years of menopause has a favorable benefit-risk profile.

  • 4

    There are significant gaps in menopause education and symptom screening among clinicians treating middle-aged women.

  • 5

    The FDA label change emphasizes the need for routine symptom assessment and individualized discussions about MHT.

Original Source(s)

Rethinking Menopause Hormone Therapy

  • by Kerri Miller

  • April 23, 2026

Related Content

Women Overdue for Cancer Screenings

More than 80% of women who were partially up to date reported a wellness visit in the prior year, suggesting missed opportunities for screening engagement in primary care.

Top 10 States for Physician-Owned Hospitals

These 10 states make it more practical for physicians to participate in hospital ownership by aligning statutory structure, corporate practice of medicine rules, and population trends.

Physicians Exiting Practice Earlier

Researchers identify burnout-associated workplace pressures and caregiving responsibilities as major contributors to physician attrition.